ϟ
DOI: 10.1158/1078-0432.22444683
¤ OpenAccess: Green
This work has “Green” OA status. This means it may cost money to access on the publisher landing page, but there is a free copy in an OA repository.
Supplementary Figure 2 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
Francesco Atzori,Josep Tabernero,Andrés Cervantes,Ludmila Prudkin,Jordi Andreu,Edith Rodríguez-Braun,Amparo Soler Domingo,Jorge Guijarro,Cristina Gámez,Jordi Rodón,Serena Di Cosimo,Holly Brown,J. A. Clark,James S. Hardwick,Robert A. Beckman,William D. Hanley,Karl Hsu,Emiliano Calvo,Susana Roselló,Ronald B. Langdon,José Baselga
Pharmacodynamics
Pharmacokinetics
Insulin-like growth factor
2023
<p>PDF file - 81K</p>
Loading...
- MLA
- APA
- Chicago
- IEEE
- Harvard
- BibTeX
Cite this:
Generate Citation
“Supplementary Figure 2 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors” is a paper by Francesco Atzori Josep Tabernero Andrés Cervantes Ludmila Prudkin Jordi Andreu Edith Rodríguez-Braun Amparo Soler Domingo Jorge Guijarro Cristina Gámez Jordi Rodón Serena Di Cosimo Holly Brown J. A. Clark James S. Hardwick Robert A. Beckman William D. Hanley Karl Hsu Emiliano Calvo Susana Roselló Ronald B. Langdon José Baselga published in 2023. It has an Open Access status of “green”. You can read and download a PDF Full Text of this paper here.